Across TCGA pan-cancer cohorts, ARHGEF34P Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated ARHGEF34P data layer compared with 22 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher ARHGEF34P Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ARHGEF34P expression acts as an unfavorable survival marker.

BLCA are the cancer types where ARHGEF34P Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.232	0.720	.014	12	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

Exploration

Same gene, other analysis: ARHGEF34P tumor-vs-normal RNA expression · all ARHGEF34P data types